Actinium-225, lead-212, and astatine-211 are the three clinically advanced alpha emitters. A review published in Trends in Pharmacological Sciences in early 2026 concluded that these three are the most promising and clinically advanced options available and identified scaling production and securing sustainable global supply as the major outstanding challenges, not any unresolved question about biological effects. Clinical review work through 2025 counted a large cohort of active early-phase alpha therapy trials worldwide, with actinium-225 driving the largest group of them and lead-212 and astatine-211 accounting for most of the remainder.
Alpha Programs Are Building on Validated Biology, Not New Targets
What distinguishes this wave from earlier alpha work is that it is not starting from scratch on target selection. The agents entering the clinic are directed largely at prostate-specific membrane antigen and the somatostatin receptor, the same biology already validated by beta-emitting therapy, and they span small molecules, peptides, and monoclonal antibodies as targeting vectors. That reuse compresses biological risk and shifts the burden onto chemistry and supply. Chelator stability is central, because a chelate that releases its payload sends free radionuclide and its decay daughters into healthy tissue, and the daughter recoil problem in the actinium-225 decay chain has no equivalent in routine lutetium-177 practice.
Several actinium-225 programs have progressed into late-stage evaluation while lead-212 programs continue through early clinical development. That divergence matters commercially, because a late-stage alpha program must evidence a secure isotope supply and a validated manufacturing process while it demonstrates efficacy. The supply risk is already evident: between October 2023 and March 2024, AstraZeneca, Bristol Myers Squibb, and Lilly each acquired an actinium-225-focused biotech, driven by the same validated PSMA and somatostatin receptor biology. The resulting surge in demand contributed to an actinium-225 shortage that forced Bristol Myers Squibb’s RayzeBio to pause a phase 3 trial the same year. The pace at which bilateral supply agreements between developers and isotope producers can absorb that demand is a live variable in any program plan, not a background detail.
Regulatory Expectations for Alpha Programs Are Being Written Now
In August 2025, the FDA issued draft guidance titled Oncology Therapeutic Radiopharmaceuticals, Dosage Optimization During Clinical Development, under docket FDA-2025-D-1757. The document is still a draft and has no binding effect. The comment period closed in October 2025, and no final version had been issued at the time of writing. Its direction is nonetheless unambiguous. It questions continued reliance on maximum tolerated dose approaches inherited from external beam radiation therapy, calls for detailed dosimetry methodology covering calibration, segmentation, modeling assumptions, and uncertainty, encourages biologically effective dose calculations to support cross-study comparison, and anticipates monitoring for late radiation events for years after the final administration. The American Society for Radiation Oncology, commenting in October 2025, supported the guidance and pressed for biologically standardized dose in preference to physical absorbed dose.
Licensing expectations are moving on a parallel track. The Advisory Committee on the Medical Uses of Isotopes at the US Nuclear Regulatory Commission has reviewed draft staff guidance on licensing the use of alpha-emitting nuclides in radiopharmaceutical therapy, which is the licensing counterpart to the clinical framework the FDA is building. Radiopharmaceuticals USA 2027 brings these priorities together, covering alpha-emitter platform selection, chelator and decay-daughter management, dosimetry under the emerging FDA framework, treatment-site radiation safety, and the isotope supply commitments that late-stage alpha programs must demonstrate before filing.
